Clinical Trials Logo

Ischemic Heart Disease clinical trials

View clinical trials related to Ischemic Heart Disease.

Filter by:

NCT ID: NCT03870815 Recruiting - Clinical trials for Ischemic Heart Disease

Long-term Outcomes and Prognostic Factors in Patient Undergoing CABG or PCI

Start date: February 27, 2019
Phase:
Study type: Observational

1. To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease undergoing coronary artery bypass graft surgery. 2. To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease undergoing percutaneous coronary intervention with drug-eluting stent.

NCT ID: NCT03855891 Completed - Atherosclerosis Clinical Trials

Micro-RNA Profile in Patients With Different Stages of Atherosclerosis According to CTA

CT-CA-miRNA
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The main purpose of this single-center study is to determine the spectrum and levels of cardiospecific circulating microRNAs in patients with different stages of atherosclerosis according to 640-slice multispiral computed tomography (MSCT).

NCT ID: NCT03847753 Completed - Stroke Clinical Trials

Exploring the Comorbidity Between Mental Disorders and General Medical Conditions

COMO-GMC
Start date: January 1, 2000
Phase:
Study type: Observational [Patient Registry]

Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions). The investigators aim to undertake a comprehensive study of comorbidity among those with treated mental disorders, by using high-quality Danish registers to provide age- and sex-specific pairwise estimates between the ten groups of mental disorders and nine groups of general medical conditions. The investigators will examine the association between all 90 possible pairs of prior mental disorders and later GMC categories using the Danish national registers. Depending on whether individuals are diagnosed with a specific mental disorder, the investigators will estimate the risk of receiving a later diagnosis within a specific GMC category, between the start of follow-up (January 1, 2000) or at the earliest age at which a person might develop the mental disorder, whichever comes later. Follow-up will be terminated at onset of the GMC, death, emigration from Denmark, or December 31, 2016, whichever came first. Additionally for dyslipidemia, follow-up will be ended if a diagnosis of ischemic heart disease was received. A "wash-out" period will be employed in the five years before follow-up started (1995-1999), to identify and exclude prevalent cases from the analysis. Individuals with the GMC of interest before the observation period will be considered prevalent cases and excluded from the analyses (i.e. prevalent cases were "washed-out"). When estimating the risk of a specific GMC, the investigators will consider all individuals to be exposed or unexposed to the each mental disorder depending on whether a diagnosis is received before the end of follow-up. Persons will be considered unexposed to a mental disorder until the date of the first diagnosis, and exposed thereafter.

NCT ID: NCT03795714 Recruiting - Clinical trials for Ischemic Heart Disease

Association Between IVUS and OCT Parameters and Invasive Physiologic Indices

Start date: November 17, 2017
Phase:
Study type: Observational

1. to evaluate diagnostic accuracy and performance of IVUS and OCT-derived quantitative parameters to predict functional significance of stenosis defined using all the available physiologic indices. 2. to explores the association between intravascular imaging-derived plaque characteristics and invasive physiologic indices.

NCT ID: NCT03791788 Completed - Clinical trials for Ischemic Heart Disease

Multicenter Registry for Angiography-Derived Quantitative Flow Ratio

QFRRegistry
Start date: April 30, 2016
Phase:
Study type: Observational

1. to investigate the feasibility and diagnostic performance of contrast quantitative flow ratio (QFR) for identifying the functional significance of intermediate degree stenotic lesions in all-comer patients with coronary artery disease (CAD) including presentation of acute myocardial infarction (AMI) with non-culprit lesion. 2. to compare the changes of contrast QFR and fractional flow reserve (FFR) according to severity of percent diameter stenosis (%DS) 3. to evaluate prognostic implication of contrast QFR in comparison with FFR

NCT ID: NCT03786965 Recruiting - Clinical trials for Ischemic Heart Disease

Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.

MPO-CSP
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.

NCT ID: NCT03786939 Recruiting - Clinical trials for Ischemic Heart Disease

Evaluation of Outcomes of Coronary Artery Bypass Grafting.

EOCABG
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

Evaluation of outcomes of coronary artery bypass grafting.

NCT ID: NCT03780803 Completed - Clinical trials for Pulmonary Hypertension

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and body mass composition in patients with pulmonary arterial hypertension (PAH) or left ventricular heart failure with reduced ejection fraction - HFREF), or ischemic heart disease and evaluation the number of stem cells, natural lymphoid cells and distribution of subpopulations of monocytes (including proangiogenic monocytes) in examined persons and evaluation of theirs eventual influence of the course of disease.

NCT ID: NCT03779217 Completed - Clinical trials for Cardiovascular Diseases

Breast Disease and Cardiovascular Disease

Start date: January 2, 2008
Phase:
Study type: Observational

Cardiovascular disease (CVD) occurs less frequently in women than in juvenile men.Frequently the estrogen deficiency associated with the menopausal state affects cardiovascular outcomes. In fact, in the post-menopausal state, even younger women may experience an increase in the rate of ischemic heart disease (IHD). On the other hand, CVD may also occur in premenopausal young women, due to not well known and/or not clearly investigated mechanisms. In addition, pre-menopausal women with IHD show atypical symptoms and more frequently myocardial infarction vs. angina pectoris. In detail, in these patients IHD is frequently due to mono-vessel coronary heart disease, and to the presence of cardiovascular risk factors such as hypertension, hyperlipidemia and type 2 diabetes. So, it is clear that all these pro-atherogenic risk factors which lead to IHD in women, are significantly lower in the pre-menopausal vs. post-menopausal patients. However, the causes leading to IHD and acute coronary events in pre-menopausal women remain poorly understood and poorly investigated, and these factors might be different from the traditional coronary risk factors evident in the general population. In this context, recently some authors have shown that subcutaneous abdominal fat affects cardiovascular performance at 1 year of follow-up in patients with normoglycemia vs. pre-diabetic. Therefore, here authors can hypothesize that in a population of female subjects, the fat tissue present in the mammary gland and the different degrees of mammary adipocyte infiltration can somehow invalidate the number of cardiovascular events in women of childbearing age. In detail, the different distribution of adipose tissue in the mammary gland can influence the density of the breast, as studied by mammographic examination, which is used to divide breast density into 4 different categories: - Category A: the breast is represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue. - Category B: the breast is represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue. - Category C: the breast is represented by fatty tissuein the range 25-50% and the rest is from fibro-glandular tissue - Category D: the breast is represented by almost entirely fibro-glandular tissue. Therefore, in the present study authors correlated the 4 different breast categories with CVD and 10-year follow-up IHD in women of child-bearing age. In fact, according to authors' opinion, a breast with higher fat density (category A) might influence the number of adverse cardiovascular events at 10-year follow-up in asymptomatic women. Thus, pre-menopausal women with breast tissue in category A ("fatty breast") as compared to women with prevalence of fibro-glandular tissue ("non-fatty breast") may have a higher frequency of adverse cardiac ischemic events at 10 years of follow-up. On the other hand, the molecular pathways implied in worse CVD in these cohorts of women are not fully investigated. Furthermore, the authors aimed to investigate the expression of inflammatory cytokines and sodium glucose transporter 2 (SGLT2) protein expression, as markers of over-inflammation, at level of breast gland in these cohorts of women. Thus, these markers were analyzed in the breast fat tissue excissed from the fatty vs. non-fatty breast women.

NCT ID: NCT03772613 Completed - Clinical trials for Coronary Artery Disease

The Randomized OPTIMAL-ACT Trial

Start date: February 8, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes